French researchers have designed a decoy version of fibroblast growth factor receptor 3 that increased bone length and decreased achondroplasia-associated complications in mice compared with vehicle. The molecule has a longer half-life than other clinical dwarfism candidates focused on correcting abnormal signaling by the receptor.